Clinical Trial: Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer

U.S., Sept. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07180056) titled 'Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer' on Sept. 11.

Brief Summary: To evaluate the efficacy and safety of adjuvant CDK4/6 inhibitors in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.

Study Start Date: Sept., 2025

Study Type: OBSERVATIONAL

Condition: Breast Cancer

Intervention: DRUG: CDK4/6 inhibitor

abemaciclib OR ribociclib

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Wenjin Yin

Information provided by (Responsible Party): Wenjin Yin, RenJi Hospital

Published by HT Digital Content Services with permission from Health Daily Digest....